the bar inches a little higher, page-4

thanks for the well researched info skint
Well not to detract from how thorough your answers were they tend to raise more questions regarding how SBP compares to SPH

ONYX I see only has one drug in development which is the same as SBP but has a market cap around $3.5 Billion while SBP has a sub $12M market cap about 1/300 that of Onyx

why the big difference??? probably stage of development, this seems to be around 6 years behind onyx which had 163 patients in a phase 1 back in 2002

Between 2002 and 2004 Onyx stock rose from $4 to $60 while going through an interum phase 2 trial showing encouraging signs of tumor reduction.

Flip side is the phase 2 results for ONYX could have been poor in which case the stock would still be $4

SO my conclusion is its possible this stock could also go up 1400 % in the next few years or it could go back to 1 cent.